Why the study?
Does the APOC-II polymorphism affect quantitative serum lipoprotein levels in Nigerian blacks?
Does the APOC-II polymorphism affect quantitative serum lipoprotein levels in Nigerian blacks?
The APOC-II*2 allele is associated with lower total and LDL cholesterol levels in Nigerian blacks, independent of variation at the linked apoE locus.
APOC-II*2 may modestly lower cholesterol in Nigerian blacks; leaves open causal effects on CVD risk or need for replication.
The human apolipoprotein C-II locus exhibits genetically determined structural polymorphism in United States and African blacks. In the present study, we have investigated the effect of the apoC-II polymorphism on quantitative serum levels of total cholesterol, total high density lipoprotein (HDL) cholesterol, cholesterol in high density lipoprotein subfractions, low density lipoprotein (LDL) cholesterol, and triglycerides (TG) in a sample of 368 unrelated Nigerian blacks. The frequencies of the APOC-II*1 and APOC-II*2 alleles in the samples were 0.947 and 0.053, respectively. In males, the effect of the APOC-II*2 allele was to lower the total serum cholesterol and LDL-cholesterol levels by 13.28 mg/dl and 10.55 mg/dl, respectively, relative to the common allele, APOC-II*1. In females, the effect was to lower total plasma cholesterol by 4.49 mg/dl and LDL-cholesterol by 3.21 mg/dl. The effect of apoC-II on quantitative lipoprotein levels is shown to be independent of variation at the linked apoE locus, but the products of the two loci interact in determining overall quantitative phenotypes.
No takes yet. Share an insight, caveat, or question.
Sepehrnia et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: